All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
The present invention relates generally to devices that are implanted within the eye. More particularly, the present invention relates to systems, devices and methods for delivering ocular implants into the eye.
According to a draft report by The National Eye Institute (NEI) at The United States National Institutes of Health (NIH), glaucoma is now the leading cause of irreversible blindness worldwide and the second leading cause of blindness, behind cataract, in the world. Thus, the NEI draft report concludes, “it is critical that significant emphasis and resources continue to be devoted to determining the pathophysiology and management of this disease.” Glaucoma researchers have found a strong correlation between high intraocular pressure and glaucoma. For this reason, eye care professionals routinely screen patients for glaucoma by measuring intraocular pressure using a device known as a tonometer. Many modern tonometers make this measurement by blowing a sudden puff of air against the outer surface of the eye.
The eye can be conceptualized as a ball filled with fluid. There are two types of fluid inside the eye. The cavity behind the lens is filled with a viscous fluid known as vitreous humor. The cavities in front of the lens are filled with a fluid know as aqueous humor. Whenever a person views an object, he or she is viewing that object through both the vitreous humor and the aqueous humor.
Whenever a person views an object, he or she is also viewing that object through the cornea and the lens of the eye. In order to be transparent, the cornea and the lens can include no blood vessels. Accordingly, no blood flows through the cornea and the lens to provide nutrition to these tissues and to remove wastes from these tissues. Instead, these functions are performed by the aqueous humor. A continuous flow of aqueous humor through the eye provides nutrition to portions of the eye (e.g., the cornea and the lens) that have no blood vessels. This flow of aqueous humor also removes waste from these tissues.
Aqueous humor is produced by an organ known as the ciliary body. The ciliary body includes epithelial cells that continuously secrete aqueous humor. In a healthy eye, a stream of aqueous humor flows out of the anterior chamber of the eye through the trabecular meshwork and into Schlemm's canal as new aqueous humor is secreted by the epithelial cells of the ciliary body. This excess aqueous humor enters the venous blood stream from Schlemm's canal and is carried along with the venous blood leaving the eye.
When the natural drainage mechanisms of the eye stop functioning properly, the pressure inside the eye begins to rise. Researchers have theorized prolonged exposure to high intraocular pressure causes damage to the optic nerve that transmits sensory information from the eye to the brain. This damage to the optic nerve results in loss of peripheral vision. As glaucoma progresses, more and more of the visual field is lost until the patient is completely blind.
In addition to drug treatments, a variety of surgical treatments for glaucoma have been performed. For example, shunts were implanted to direct aqueous humor from the anterior chamber to the extraocular vein (Lee and Scheppens, “Aqueous-venous shunt and intraocular pressure,” Investigative Ophthalmology (February 1966)). Other early glaucoma treatment implants led from the anterior chamber to a sub-conjunctival bleb (e.g., U.S. Pat. Nos. 4,968,296 and 5,180,362). Still others were shunts leading from the anterior chamber to a point just inside Schlemm's canal (Spiegel et al., “Schlemm's canal implant: a new method to lower intraocular pressure in patients with POAG?” Ophthalmic Surgery and Lasers (June 1999); U.S. Pat. Nos. 6,450,984; 6,450,984). More recent glaucoma treatment implants are designed to be advanced into and placed in Schlemm's canal. (See, e.g., U.S. Pat. No. 7,740,604; US 2011/0009958.)
The present invention relates to methods and devices for treating glaucoma. In particular, the invention relates to an implant designed to extend from the anterior chamber of a human eye into Schlemm's canal and to support the tissue of Schlemm's canal to support flow of aqueous humor from the anterior chamber into Schlemm's canal to the outflow channels communicating with Schlemm's canal.
In one aspect, the invention provides an ocular implant adapted to be disposed within Schlemm's canal of a human eye and configured to support Schlemm's canal in an open state. The ocular implant has a body extending along a curved longitudinal central axis in a curvature plane, the body having a central channel bordered by an opening, first and second frames and a spine interposed between the first and second frames, the spine having a circumferential extent, the body having dimensions adapted to be fit within Schlemm's canal; each frame comprising a first strut on one side of the implant and a second strut on an opposite side of the implant, the first strut extending circumferentially beyond the circumferential extent of the spine on the one side of the implant and the second strut extending circumferentially beyond the circumferential extent of the spine on the other side of the implant, the circumferential extent of the first strut with respect to the plane of curvature being greater than the circumferential extent of the second strut with respect to the plane of curvature. In some embodiments, the body has a curved resting shape.
The implant may be adapted to bend preferentially in a preferential bending direction. In some embodiments, the preferential bending direction is in the curvature plane, and in some embodiments the preferential bending direction is not in the curvature plane.
In some embodiments, the circumferential extent of the first strut beyond the circumferential extent of the spine on the one side of the implant is greater than the circumferential extent of the second strut beyond the circumferential extent of the spine on the other side of the implant.
In embodiments in which the implant also has a third frame and a second spine interposed between the second and third frames, the second spine having a circumferential extent, the third frame having a first strut on one side of the implant and a second strut on an opposite side of the implant, the first strut and second strut of the third frame each having a circumferential extent greater than the circumferential extent of the second spine, the circumferential extent of the first strut with respect to the plane of curvature may be greater than the circumferential extent of the second strut with respect to the plane of curvature. The first, second and third frames may be substantially identical, and the first and second spines may be substantially identical. In some embodiments, the first spine is adapted to bend preferentially in a first bending direction, and the second spine is adapted to bend preferentially in a second bending direction different from the first bending direction.
In some embodiments, the plane of curvature intersects the spine. The spine may extend circumferentially in substantially equal amounts from the plane of curvature.
In some embodiments, the opening is an elongated opening extending longitudinally along the frames and the spine. The implant may also have a second opening bordered by the first and second struts of the first frame and a third opening bordered by the first and second struts of the second frame.
Another aspect of the invention provides a method of treating glaucoma in a human eye. The method may include the following steps: inserting a cannula through a cornea of the eye into an anterior chamber of the eye; placing a distal opening of the cannula in communication with Schlemm's canal of the eye; moving an ocular implant out of the cannula through the opening and into Schlemm's canal, the ocular implant having a central channel and first and second landing surfaces, the first and second landing surfaces being disposed on opposite sides of the central channel; and engaging a scleral wall of Schlemm's canal with the first and second landing surfaces such that reaction forces on the first and second landing surfaces from engagement with the scleral wall are substantially equal.
In some embodiments, the engaging step includes the step of engaging the scleral wall of Schlemm's canal with the first and second landing surfaces without substantially twisting the ocular implant.
In some embodiments, the implant has a resting shape forming a curve, and the method includes the step of orienting the implant curve with a curve of Schlemm's canal.
In some embodiments, the cannula is curved at a distal end, and the method includes the step of orienting the cannula for tangential delivery of the implant from the cannula into Schlemm's canal.
The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.
During the exemplary procedure illustrated in
Methods in accordance with this detailed description may include the step of advancing the distal end of cannula 72 through the cornea of eye 20 so that a distal portion of cannula 72 is disposed in the anterior chamber of the eye. Cannula 72 may then be used to access Schlemm's canal of the eye, for example, by piercing the wall of Schlemm's canal with the distal end of cannula 72. A distal opening of cannula 72 may be placed in fluid communication with a lumen defined by Schlemm's canal. The ocular implant may be advanced out of the cannula and into Schlemm's canal. Insertion of the ocular implant into Schlemm's canal may facilitate the flow of aqueous humor out of the anterior chamber of the eye.
In the embodiment of
Whenever a person views an object, he or she is viewing that object through the cornea, the aqueous humor, and the lens of the eye. In order to be transparent, the cornea and the lens can include no blood vessels. Accordingly, no blood flows through the cornea and the lens to provide nutrition to these tissues and to remove wastes from these tissues. Instead, these functions are performed by the aqueous humor. A continuous flow of aqueous humor through the eye provides nutrition to portions of the eye (e.g., the cornea and the lens) that have no blood vessels. This flow of aqueous humor also removes waste from these tissues.
Aqueous humor is produced by an organ known as the ciliary body. The ciliary body includes epithelial cells that continuously secrete aqueous humor. In a healthy eye, a stream of aqueous humor flows out of the eye as new aqueous humor is secreted by the epithelial cells of the ciliary body. This excess aqueous humor enters the blood stream and is carried away by venous blood leaving the eye.
With reference to
Because of the position of Schlemm's canal SC within the anterior chamber AC, a Schlemm's canal access cannula inserted through the cornea 36 and anterior chamber AC is likely to approach the plane of Schlemm's canal at an approach angle that is greater than zero. Thus, for example, when using a curved cannula (such as the one shown in
As shown in the previous figure, Schlemm's canal is disposed inside anterior chamber AC. An exemplary method in accordance with this detailed description may include the step of advancing a distal portion of a cannula into the anterior chamber of the eye. The cannula may then be used to access Schlemm's canal, for example, by piercing the wall of Schlemm's canal with the distal end of the cannula. An ocular implant may be advanced out of the distal opening of the cannula and into Schlemm's canal. An exemplary path 94 taken by an ocular implant as it follows Schlemm's canal along surface 92 is illustrated using a row of dots in
As the ocular implant advances into Schlemm's canal, the ocular implant may press against the outer major wall of Schlemm's canal and the dome-shaped wall that defines the anterior chamber of the eye. As the body of the ocular implant presses against the dome-shaped wall of the eye, the dome-shaped wall provides support for Schlemm's canal and the ocular implant. The support provided by the dome-shaped wall may be represented by force vectors. The direction of these force vectors may be at right angles to points on the spherical surface that defines the anterior chamber. The dome shaped wall comprises scleral tissue that is firmer than the tissue of Schlemm's canal wall. Accordingly, the outer major wall of Schlemm's canal may be supported by the dome shaped wall as the ocular implant advances into Schlemm's canal.
During delivery, it is desirable that the ocular implant follow the lumen of Schlemm's canal as it is advanced out the distal opening of the cannula. The ability of the ocular implant to be advanced into and follow the lumen of Schlemm's canal may be referred to as trackability. Characteristics of an ocular implant that affect trackability include axial pushability, lateral flexibility, and overall shape with respect to the shape of Schlemm's canal (e.g., radius of curvature and cross-section profile). Axial pushability generally concerns the ability of an ocular implant to transmit to the distal end of the ocular implant an axial force applied to the proximal end of the ocular implant. Lateral flexibility concerns the ease with which the ocular implant body can bend to conform to the shape of the lumen. Trackability may be adversely effected when twisting forces are applied to a curved body. For example, twisting the body of a curved ocular implant about its longitudinal axis may cause the curved body to steer away from a desired path.
The length of major axis 60 and minor axis 62 can vary from patient to patient. The length of minor axis 62 is between one and thirty micrometers in most patients. The length of major axis 60 is between one hundred and fifty micrometers and three hundred and fifty micrometers in most patients.
With reference to
An exemplary path 94 taken by an ocular implant as it follows Schlemm's canal along surface 92 is illustrated using a row of dots in
The interaction between the implant's structure and the tissue forming Schlemm's canal can affect how the implant behaves as it is inserted into and advanced along Schlemm's canal. For example, the implant may have surfaces (hereinafter, “landing surfaces”) that engage scleral tissue within Schlemm's canal as the implant is inserted into and advanced along Schlemm's canal. If the force vector on a landing surface on one side of the implant exceeds the force vector on an opposite side of the implant, the implant may bend or twist as it is advanced. In addition, if the implant has a preset curve, any bending or twisting of the implant may direct the curve away from, instead of along, the curve of Schlemm's canal. Also, the implant may have a preferential bending plane that will affect the orientation of the implant within a curved insertion cannula and with the curve of Schlemm's canal as well as the implant's response to force vectors on its landing surfaces.
For example, an ocular implant in accordance with the present detailed description may include a plurality of spines and a plurality of landing surfaces that seat against the inner surface of the dome shaped wall that encloses the anterior chamber so that the dome shaped wall provides supporting normal forces to the landing surfaces. The ocular implant may be configured such that a net twisting moment applied to each spine by the normal forces supporting the landing surfaces during implantation is reduced or is substantially zero. The ocular implant may also be configured such that the normal forces supporting the landing surfaces primarily or exclusively act to guide each spine along the preferential bending plane thereof.
In some embodiments, as shown in
Placing
Ocular implant 500 of
As shown in
With reference to
A plane 524 is shown intersecting ocular implant 500 in
As an ocular implant advances into Schlemm's canal during a delivery procedure, the ocular implant may press against the dome-shaped wall that defines the anterior chamber. More particularly, one or more struts of the ocular implant may press against scleral tissue forming part of the dome-shaped wall of the eye. Landing surfaces of the ocular implant may be seated against the outer wall of Schlemm's canal and the scleral tissue as it is advanced into Schlemm's canal. The scleral tissue may provide support for the outer wall of Schlemm's canal as the ocular implant is advanced therein. These supporting reaction forces will act against the ocular implant as the implant engages the wall of Schlemm's canal.
For example, as discussed above with respect to
Changing the angle of the insertion cannula with respect to the plane of Schlemm's canal would change the way the implant's landing surfaces interact with scleral tissue during insertion and, therefore, any bending or twisting moments applied to the implant. Visualization requirements and anterior chamber access limitations may require the cannula to form an angle greater than zero with the plane of Schlemm's canal. It therefore may be desirable to change the position of the implant landing surfaces in an effort to reduce the difference in the magnitude of the reaction forces on landing surfaces on opposite sides of the implant, such as by changing the relative heights of the struts with respect to the implant's plane of curvature.
Ocular implant 100 of
A plane 124 is shown intersecting ocular implant 100 in
During implantation, the implant 100 will be oriented with the curved insertion cannula 72, as suggested by
A roll angle RB of frame 106 is illustrated using angular dimension lines in
Differences in the responses of implant 100 and implant 500 can be seen by comparing
Applicant has created ocular implants designed to work in harmony with the dome shaped wall that defines the anterior chamber of the human eye. In some useful embodiments, the ocular implants are configured such that reaction forces applied to the ocular implant by scleral tissue while the ocular implant is being advanced into Schlemm's canal subject the ocular implant to pure bending with little or no twisting. The ocular implant may be configured such that a net twisting moment applied to each spine by the normal forces supporting the landing surfaces is substantially zero. The ocular implant may also be configured such that the normal forces supporting the landing surfaces primarily or exclusively act to bend each spine along the preferential bending plane thereof.
The implant will bend preferentially about the region having the smallest circumferential extent, i.e., the spine. In the embodiment shown
In the embodiment of
Ocular implant 100 of
In
Body 102 of ocular implant 100 defines a channel 132 that opens into a channel opening 134. With reference to
With particular reference to
Ocular implant 100 of
In
Body 102 of ocular implant 100 defines a channel 132 that opens into a channel opening 134. With particular reference to
Body 102 of ocular implant 100 has a distal end 126, a proximal inlet portion 128 and an intermediate portion 130 extending between the proximal inlet portion 128 and the distal end 126. Intermediate portion 130 comprises a plurality of spines 104 and a plurality of frames 106. The frames 106 of intermediate portion 130 include a first frame 106A, a second frame 106B and a third frame 106C. In
The spines 104 of intermediate portion 130 include a first spine 104A, a second spine 104B and a third spine 104C. In
With reference to
In the exemplary embodiment of
First frame 106A of
A roll angle RA of first frame 106A is illustrated using angular dimension lines in
Ocular implant 300 of
In
Body 302 of ocular implant 300 defines a channel 332 that opens into a channel opening 334. With reference to
Ocular implant 300 of
In
Body 302 of ocular implant 300 defines a channel 332 that opens into a channel opening 334. With reference to
In the embodiment of
A second plane 324B and a third plane 324C are shown extending transversely across body 302 of ocular implant 300 in
Body 302 of ocular implant 300 has a distal end 326, a proximal inlet portion 328 and an intermediate portion 330 extending between the proximal inlet portion 328 and the distal end 326. Intermediate portion 330 comprises a plurality of spines 304 and a plurality of frames 306. The frames 306 of intermediate portion 330 include a proximal-most frame 306A, an intermediate frame 306B and a distal-most frame 306C. Second plane 324B is shown extending through distal-most frame 306C in
The spines 304 of intermediate portion 330 include a proximal-most spine 304A, an intermediate spine 304B and a distal-most spine 304C. In
In
In the embodiment of
Upon advancement of ocular implant 300 into Schlemm's canal, and depending on the angle of the delivery cannula with respect to the plane of Schlemm's canal during insertion, first landing surface 342E of first strut 308E and second landing surface 342F of second strut 308F may seat against the inner surface of the dome shaped wall that encloses the anterior chamber with the dome shaped wall providing normal forces supporting the landing surfaces. In some useful embodiments, roll angle RA is selected such that, when ocular implant 300 is advanced into Schlemm's canal landing surfaces of first strut 308E and second strut 308F are seated against the dome-shaped wall that defines the anterior chamber of the eye with substantially equal force. The decrease in the difference between the reaction forces on opposite sides of the implant will decrease any bending or twisting moments applied to implant 300 during insertion and advancement within Schlemm's canal.
In the embodiment of
Upon advancement of ocular implant 300 into Schlemm's canal, the landing surfaces may seat against the inner surface of the dome shaped wall that encloses the anterior chamber with the dome shaped wall providing normal forces supporting the landing surfaces. Each spine of ocular implant 300 may be configured to preferentially bend along a preferential bending plane. In some useful embodiments, each spine is rotationally offset relative to a first adjacent frame and a second adjacent frame by an angle selected such that the normal forces supporting the landing surfaces primarily or exclusively act to bend each spine along the preferential bending plane thereof. In some useful embodiments, each spine is rotationally offset relative to a first adjacent frame and a second adjacent frame by an angle selected such that a net twisting moment applied to each spine by the normal forces is substantially zero. The arrangement described above may minimize any twisting of the ocular implant body as the ocular implant is advanced into Schlemm's canal as part of a delivery procedure. This arrangement may also provide better trackability than devices that do not include these design features.
As shown in
With reference to
The profiles of first strut 308E and second strut 308F are labeled PE and PF in
Distal-most spine 304C of
In the embodiment of
Ocular implant 100 includes a distal-most spine 104C, and ocular implant 300 includes a distal-most spine 304C. As shown in
In
First frame 306A comprises a first strut 308A and a second strut 308B. First strut 308A and second strut 308B comprise a first landing surface 342A and a second landing surface 342B, respectively. First landing surface 342A of first strut 308A and second landing surface 342B of second strut 308B define a first footprint line 338A. Second frame 306B comprises a first strut 308C and a second strut 308D. First strut 308C comprises a first landing surface 342C and second strut 308D comprises a second landing surface 342D. First landing surface 342C of first strut 308C and second landing surface 342D of fourth strut 308D define a second footprint line 338B. Third frame 306C includes a first strut 308E and a second strut 308F. First strut 308E and second strut 308F have a first landing surface 342E and a second landing surface 342F, respectively. First landing surface 342E of first strut 308E and second landing surface 342F of second strut 308F define a third footprint line 338C. In
Body 302 of ocular implant 300 has a distal end 326, a proximal inlet portion 328 and an intermediate portion 330 extending between proximal inlet portion 328 and distal end 326. Intermediate portion 330 of body 302 includes first frame 306A, second frame 306B, third frame 306C and a plurality of spines 304. The spines 304 of intermediate portion 330 include a first spine 304A, a second spine 304B and a third spine 304C. In
In the embodiment of
For purposes of illustration, a window 70 is cut through first major side 50 of Schlemm's canal SC in
In the embodiment of
While exemplary embodiments of the present invention have been shown and described, modifications may be made, and it is therefore intended in the appended claims to cover all such changes and modifications which fall within the true spirit and scope of the invention.
This application is a division of U.S. application Ser. No. 13/793,638, filed Mar. 11, 2013, which application claims the benefit under 35 U.S.C. § 119 of U.S. Provisional Application No. 61/635,104, filed Apr. 18, 2012, the disclosures of which are incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
703296 | Arnold | Jun 1902 | A |
1601709 | Windom | Oct 1926 | A |
2716983 | George et al. | Sep 1955 | A |
3071135 | Baldwin et al. | Jan 1963 | A |
3788327 | Donowitz et al. | Jan 1974 | A |
3811442 | Maroth | May 1974 | A |
3858577 | Bass et al. | Jan 1975 | A |
3884236 | Krasnov | May 1975 | A |
3948271 | Akiyama | Apr 1976 | A |
3982541 | L'Esperance | Sep 1976 | A |
4037604 | Newkirk | Jul 1977 | A |
4134405 | Smit | Jan 1979 | A |
4273109 | Enderby | Jun 1981 | A |
4391275 | Fankhauser et al. | Jul 1983 | A |
4428746 | Mendez | Jan 1984 | A |
4457757 | Molteno | Jul 1984 | A |
4461294 | Baron | Jul 1984 | A |
4470407 | Hussein | Sep 1984 | A |
4497319 | Sekine et al. | Feb 1985 | A |
4501274 | Skjaerpe | Feb 1985 | A |
4517973 | Sunago et al. | May 1985 | A |
4538608 | L'Esperance | Sep 1985 | A |
4551129 | Coleman et al. | Nov 1985 | A |
4558698 | O'Dell | Dec 1985 | A |
4559942 | Eisenberg | Dec 1985 | A |
4566438 | Liese et al. | Jan 1986 | A |
4580559 | L'Esperance | Apr 1986 | A |
4583539 | Karlin et al. | Apr 1986 | A |
4601713 | Fuquo | Jul 1986 | A |
4604087 | Joseph | Aug 1986 | A |
4633866 | Peyman et al. | Jan 1987 | A |
4658816 | Ector | Apr 1987 | A |
4660546 | Herrick et al. | Apr 1987 | A |
4671273 | Lindsey | Jun 1987 | A |
4689040 | Thompson | Aug 1987 | A |
4699140 | Holmes et al. | Oct 1987 | A |
4706669 | Schlegel | Nov 1987 | A |
4722350 | Armeniades et al. | Feb 1988 | A |
4722724 | Schocket | Feb 1988 | A |
4729373 | Peyman | Mar 1988 | A |
4733665 | Palmaz | Mar 1988 | A |
4750901 | Molteno | Jun 1988 | A |
4770654 | Rogers et al. | Sep 1988 | A |
4791927 | Menger | Dec 1988 | A |
4826478 | Schocket | May 1989 | A |
4846172 | Berlin | Jul 1989 | A |
4861341 | Woodburn | Aug 1989 | A |
4876250 | Clark | Oct 1989 | A |
4880000 | Holmes et al. | Nov 1989 | A |
4886488 | White | Dec 1989 | A |
4919130 | Stoy et al. | Apr 1990 | A |
4925299 | Meisberger et al. | May 1990 | A |
4934363 | Smith et al. | Jun 1990 | A |
4934809 | Volk | Jun 1990 | A |
4936825 | Ungerleider | Jun 1990 | A |
4946436 | Smith | Aug 1990 | A |
4968296 | Ritch et al. | Nov 1990 | A |
4994060 | Rink et al. | Feb 1991 | A |
5034010 | Kittrell et al. | Jul 1991 | A |
5092837 | Ritch et al. | Mar 1992 | A |
5123902 | Muller et al. | Jun 1992 | A |
5127901 | Odrich | Jul 1992 | A |
5129895 | Vassiliadis et al. | Jul 1992 | A |
5178604 | Baerveldt et al. | Jan 1993 | A |
5180362 | Worst | Jan 1993 | A |
5190552 | Kelman | Mar 1993 | A |
5213569 | Davis | May 1993 | A |
5246452 | Sinnott | Sep 1993 | A |
5254112 | Sinofsky et al. | Oct 1993 | A |
5273056 | McLaughlin et al. | Dec 1993 | A |
5290267 | Zimmermann | Mar 1994 | A |
5300020 | L'Esperance, Jr. | Apr 1994 | A |
5359685 | Waynant et al. | Oct 1994 | A |
5360399 | Stegmann | Nov 1994 | A |
5371078 | Clark et al. | Dec 1994 | A |
5372577 | Ungerleider | Dec 1994 | A |
5445637 | Bretton | Aug 1995 | A |
5454796 | Krupin | Oct 1995 | A |
5458615 | Klemm et al. | Oct 1995 | A |
5501274 | Nguyen et al. | Mar 1996 | A |
5536259 | Utterberg | Jul 1996 | A |
5575780 | Saito | Nov 1996 | A |
5591223 | Lock et al. | Jan 1997 | A |
5607966 | Hellberg et al. | Mar 1997 | A |
5613972 | Lee et al. | Mar 1997 | A |
5626558 | Suson | May 1997 | A |
5643250 | O'Donnell, Jr. | Jul 1997 | A |
5653753 | Brady et al. | Aug 1997 | A |
5657760 | Ying et al. | Aug 1997 | A |
5676669 | Colvard | Oct 1997 | A |
5704907 | Nordquist et al. | Jan 1998 | A |
5713844 | Peyman | Feb 1998 | A |
5722970 | Colvard et al. | Mar 1998 | A |
5736491 | Patel et al. | Apr 1998 | A |
5738676 | Hammer et al. | Apr 1998 | A |
5738677 | Colvard et al. | Apr 1998 | A |
5785658 | Benaron et al. | Jul 1998 | A |
5792099 | DeCamp et al. | Aug 1998 | A |
5792103 | Schwartz et al. | Aug 1998 | A |
5807302 | Wandel | Sep 1998 | A |
5811453 | Yanni et al. | Sep 1998 | A |
5865831 | Cozean et al. | Feb 1999 | A |
5868697 | Richter et al. | Feb 1999 | A |
5879319 | Pynson et al. | Mar 1999 | A |
5885279 | Bretton | Mar 1999 | A |
5893837 | Eagles et al. | Apr 1999 | A |
5895831 | Brasier et al. | Apr 1999 | A |
5919171 | Kira et al. | Jul 1999 | A |
5948427 | Yamamoto et al. | Sep 1999 | A |
5968058 | Richter et al. | Oct 1999 | A |
5990099 | Clark | Nov 1999 | A |
5993438 | Juhasz et al. | Nov 1999 | A |
5997531 | Loeb et al. | Dec 1999 | A |
6002480 | Izatt et al. | Dec 1999 | A |
6007511 | Prywes | Dec 1999 | A |
6050970 | Baerveldt | Apr 2000 | A |
6083193 | Kadziauskas et al. | Jul 2000 | A |
6099521 | Shadduck | Aug 2000 | A |
6102045 | Nordquist et al. | Aug 2000 | A |
6146375 | Juhasz et al. | Nov 2000 | A |
6177544 | Kanai et al. | Jan 2001 | B1 |
6186974 | Allan et al. | Feb 2001 | B1 |
6217584 | Nun | Apr 2001 | B1 |
6221078 | Bylsma | Apr 2001 | B1 |
6238409 | Hojeibane | May 2001 | B1 |
6241721 | Cozean et al. | Jun 2001 | B1 |
D444874 | Haffner et al. | Jul 2001 | S |
6297228 | Clark | Oct 2001 | B1 |
6319274 | Shadduck | Nov 2001 | B1 |
6328747 | Nun | Dec 2001 | B1 |
6375642 | Grieshaber et al. | Apr 2002 | B1 |
6398809 | Hoffmann et al. | Jun 2002 | B1 |
6409752 | Boatman et al. | Jun 2002 | B1 |
6450984 | Lynch et al. | Sep 2002 | B1 |
6464724 | Lynch et al. | Oct 2002 | B1 |
6471666 | Odrich | Oct 2002 | B1 |
6494857 | Neuhann | Dec 2002 | B1 |
6508779 | Suson | Jan 2003 | B1 |
6517523 | Kaneko et al. | Feb 2003 | B1 |
6524275 | Lynch et al. | Feb 2003 | B1 |
6533764 | Haffner et al. | Mar 2003 | B1 |
6533768 | Hill | Mar 2003 | B1 |
6544208 | Ethier et al. | Apr 2003 | B2 |
6544249 | Yu et al. | Apr 2003 | B1 |
6551289 | Higuchi et al. | Apr 2003 | B1 |
6626858 | Lynch et al. | Sep 2003 | B2 |
6638239 | Bergheim et al. | Oct 2003 | B1 |
6666841 | Gharib et al. | Dec 2003 | B2 |
6699210 | Williams et al. | Mar 2004 | B2 |
6699211 | Savage | Mar 2004 | B2 |
6702790 | Ross | Mar 2004 | B1 |
6726676 | Stegmann et al. | Apr 2004 | B2 |
D490152 | Myall et al. | May 2004 | S |
6730056 | Ghaem et al. | May 2004 | B1 |
6736791 | Tu et al. | May 2004 | B1 |
6780164 | Bergheim et al. | Aug 2004 | B2 |
6783544 | Lynch et al. | Aug 2004 | B2 |
6827699 | Lynch et al. | Dec 2004 | B2 |
6827700 | Lynch et al. | Dec 2004 | B2 |
6881198 | Brown | Apr 2005 | B2 |
6899717 | Weber et al. | May 2005 | B2 |
6939298 | Brown et al. | Sep 2005 | B2 |
6955656 | Bergheim et al. | Oct 2005 | B2 |
6962573 | Wilcox | Nov 2005 | B1 |
6981958 | Gharib et al. | Jan 2006 | B1 |
6989007 | Shadduck | Jan 2006 | B2 |
7018376 | Webb et al. | Mar 2006 | B2 |
7094225 | Tu et al. | Aug 2006 | B2 |
7125119 | Farberov | Oct 2006 | B2 |
7133137 | Shimmick | Nov 2006 | B2 |
7135009 | Tu et al. | Nov 2006 | B2 |
7147650 | Lee | Dec 2006 | B2 |
7163543 | Smedley et al. | Jan 2007 | B2 |
7186232 | Smedley et al. | Mar 2007 | B1 |
7192412 | Zhou et al. | Mar 2007 | B1 |
7207965 | Simon | Apr 2007 | B2 |
7207980 | Christian et al. | Apr 2007 | B2 |
7220238 | Lynch et al. | May 2007 | B2 |
7273475 | Tu et al. | Sep 2007 | B2 |
7297130 | Bergheim et al. | Nov 2007 | B2 |
7331984 | Tu et al. | Feb 2008 | B2 |
7488303 | Haffner et al. | Feb 2009 | B1 |
7699882 | Stamper et al. | Apr 2010 | B2 |
7740604 | Schieber et al. | Jun 2010 | B2 |
7931596 | Rachlin et al. | Apr 2011 | B2 |
7967772 | McKenzie et al. | Jun 2011 | B2 |
8012115 | Karageozian | Sep 2011 | B2 |
8123729 | Yamamoto et al. | Feb 2012 | B2 |
8172899 | Silvestrini et al. | May 2012 | B2 |
8267882 | Euteneuer et al. | Sep 2012 | B2 |
8282592 | Schieber et al. | Oct 2012 | B2 |
8308701 | Horvath et al. | Nov 2012 | B2 |
8337509 | Schieber et al. | Dec 2012 | B2 |
8372026 | Schieber et al. | Feb 2013 | B2 |
8414518 | Schieber et al. | Apr 2013 | B2 |
8425449 | Wardle et al. | Apr 2013 | B2 |
8475374 | Irazogui et al. | Jul 2013 | B2 |
8512404 | Frion et al. | Aug 2013 | B2 |
8529494 | Euteneuer et al. | Sep 2013 | B2 |
8540659 | Berlin | Sep 2013 | B2 |
8551166 | Schieber et al. | Oct 2013 | B2 |
8629161 | Mizuno et al. | Jan 2014 | B2 |
8636647 | Silvestrini et al. | Jan 2014 | B2 |
8647659 | Robinson et al. | Feb 2014 | B2 |
8657776 | Wardle et al. | Feb 2014 | B2 |
8663150 | Wardle et al. | Mar 2014 | B2 |
8663303 | Horvath et al. | Mar 2014 | B2 |
8734377 | Schieber et al. | May 2014 | B2 |
8808222 | Schieber et al. | Aug 2014 | B2 |
8939948 | De Juan, Jr. et al. | Jan 2015 | B2 |
8945038 | Yablonski | Feb 2015 | B2 |
8951221 | Stegmann et al. | Feb 2015 | B2 |
8961447 | Schieber et al. | Feb 2015 | B2 |
8974511 | Horvath et al. | Mar 2015 | B2 |
9039650 | Schieber et al. | May 2015 | B2 |
9050169 | Schieber et al. | Jun 2015 | B2 |
9066750 | Wardle et al. | Jun 2015 | B2 |
9066783 | Euteneuer et al. | Jun 2015 | B2 |
9155655 | Wardle et al. | Oct 2015 | B2 |
9211213 | Wardle et al. | Dec 2015 | B2 |
9226852 | Schieber et al. | Jan 2016 | B2 |
9301875 | Tu et al. | Apr 2016 | B2 |
9351874 | Schieber et al. | May 2016 | B2 |
9358156 | Wardle et al. | Jun 2016 | B2 |
9603741 | Berlin | Mar 2017 | B2 |
9636254 | Yu et al. | May 2017 | B2 |
9642746 | Berlin | May 2017 | B2 |
9693901 | Horvath et al. | Jul 2017 | B2 |
9757276 | Penhasi | Sep 2017 | B2 |
9775729 | McClain et al. | Oct 2017 | B2 |
9782293 | Doci | Oct 2017 | B2 |
9820883 | Berlin | Nov 2017 | B2 |
9833357 | Berlin | Dec 2017 | B2 |
10159601 | Berlin | Dec 2018 | B2 |
10390993 | Berlin | Aug 2019 | B1 |
20010002438 | Sepetka et al. | May 2001 | A1 |
20020003546 | Mochimaru et al. | Jan 2002 | A1 |
20020013546 | Grieshaber et al. | Jan 2002 | A1 |
20020013572 | Berlin | Jan 2002 | A1 |
20020052653 | Durgin | May 2002 | A1 |
20020072673 | Yamamoto et al. | Jun 2002 | A1 |
20020082591 | Haefliger | Jun 2002 | A1 |
20020133168 | Smedley et al. | Sep 2002 | A1 |
20020143284 | Tu et al. | Oct 2002 | A1 |
20020165504 | Sharp et al. | Nov 2002 | A1 |
20020165522 | Holmen | Nov 2002 | A1 |
20020193805 | Ott et al. | Dec 2002 | A1 |
20030004457 | Andersson | Jan 2003 | A1 |
20030014092 | Neuhann | Jan 2003 | A1 |
20030040754 | Mitchell et al. | Feb 2003 | A1 |
20030055372 | Lynch et al. | Mar 2003 | A1 |
20030060748 | Baikoff | Mar 2003 | A1 |
20030060752 | Bergheim et al. | Mar 2003 | A1 |
20030060784 | Hilgers et al. | Mar 2003 | A1 |
20030093084 | Nissan et al. | May 2003 | A1 |
20030097151 | Smedley et al. | May 2003 | A1 |
20030105456 | Lin | Jun 2003 | A1 |
20030125351 | Azuma et al. | Jul 2003 | A1 |
20030175324 | Robinson et al. | Sep 2003 | A1 |
20030181848 | Bergheim et al. | Sep 2003 | A1 |
20030187384 | Bergheim et al. | Oct 2003 | A1 |
20030212387 | Kurtz et al. | Nov 2003 | A1 |
20030229303 | Haffner et al. | Dec 2003 | A1 |
20030236483 | Ren | Dec 2003 | A1 |
20030236484 | Lynch et al. | Dec 2003 | A1 |
20040024345 | Gharib et al. | Feb 2004 | A1 |
20040024453 | Castillejos | Feb 2004 | A1 |
20040030302 | Kamata et al. | Feb 2004 | A1 |
20040070761 | Horvath et al. | Apr 2004 | A1 |
20040082939 | Berlin | Apr 2004 | A1 |
20040088048 | Richter et al. | May 2004 | A1 |
20040092856 | Dahan | May 2004 | A1 |
20040098124 | Freeman et al. | May 2004 | A1 |
20040102729 | Haffner et al. | May 2004 | A1 |
20040106975 | Solovay et al. | Jun 2004 | A1 |
20040111050 | Smedley et al. | Jun 2004 | A1 |
20040116909 | Neuberger et al. | Jun 2004 | A1 |
20040122380 | Utterberg | Jun 2004 | A1 |
20040127843 | Tu et al. | Jul 2004 | A1 |
20040147870 | Burns et al. | Jul 2004 | A1 |
20040193095 | Shadduck | Sep 2004 | A1 |
20040193262 | Shadduck | Sep 2004 | A1 |
20040199149 | Myers et al. | Oct 2004 | A1 |
20040199171 | Akahoshi | Oct 2004 | A1 |
20040210181 | Vass et al. | Oct 2004 | A1 |
20040210185 | Tu et al. | Oct 2004 | A1 |
20040216749 | Tu | Nov 2004 | A1 |
20040225357 | Worst et al. | Nov 2004 | A1 |
20040228013 | Goldstein et al. | Nov 2004 | A1 |
20040249333 | Bergheim et al. | Dec 2004 | A1 |
20040254517 | Quiroz-Mercado et al. | Dec 2004 | A1 |
20040254519 | Tu et al. | Dec 2004 | A1 |
20040254520 | Porteous et al. | Dec 2004 | A1 |
20040260228 | Lynch et al. | Dec 2004 | A1 |
20050041200 | Rich | Feb 2005 | A1 |
20050043722 | Lin | Feb 2005 | A1 |
20050049578 | Tu et al. | Mar 2005 | A1 |
20050090806 | Lynch et al. | Apr 2005 | A1 |
20050090807 | Lynch et al. | Apr 2005 | A1 |
20050101967 | Weber et al. | May 2005 | A1 |
20050107734 | Coroneo | May 2005 | A1 |
20050119601 | Lynch et al. | Jun 2005 | A9 |
20050119636 | Haffner et al. | Jun 2005 | A1 |
20050125003 | Pinchuk et al. | Jun 2005 | A1 |
20050131514 | Hijlkema et al. | Jun 2005 | A1 |
20050149114 | Cartledge et al. | Jul 2005 | A1 |
20050154443 | Linder et al. | Jul 2005 | A1 |
20050165385 | Simon | Jul 2005 | A1 |
20050192527 | Gharib et al. | Sep 2005 | A1 |
20050197667 | Chan et al. | Sep 2005 | A1 |
20050203542 | Weber et al. | Sep 2005 | A1 |
20050209549 | Bergheim et al. | Sep 2005 | A1 |
20050209550 | Bergheim et al. | Sep 2005 | A1 |
20050240168 | Neuberger et al. | Oct 2005 | A1 |
20050244464 | Hughes | Nov 2005 | A1 |
20050245916 | Connor | Nov 2005 | A1 |
20050250788 | Tu et al. | Nov 2005 | A1 |
20050260186 | Bookbinder et al. | Nov 2005 | A1 |
20050266047 | Tu et al. | Dec 2005 | A1 |
20050271704 | Tu et al. | Dec 2005 | A1 |
20050273033 | Grahn et al. | Dec 2005 | A1 |
20050277864 | Haffner et al. | Dec 2005 | A1 |
20050279369 | Lin | Dec 2005 | A1 |
20050288619 | Gharib et al. | Dec 2005 | A1 |
20050288745 | Andersen et al. | Dec 2005 | A1 |
20060020247 | Kagan et al. | Jan 2006 | A1 |
20060021623 | Miller et al. | Feb 2006 | A1 |
20060032507 | Tu | Feb 2006 | A1 |
20060052879 | Kolb | Mar 2006 | A1 |
20060069340 | Simon | Mar 2006 | A1 |
20060074375 | Bergheim et al. | Apr 2006 | A1 |
20060079828 | Brown | Apr 2006 | A1 |
20060084907 | Bergheim et al. | Apr 2006 | A1 |
20060084954 | Zadoyan et al. | Apr 2006 | A1 |
20060106370 | Baerveldt et al. | May 2006 | A1 |
20060110428 | deJuan et al. | May 2006 | A1 |
20060116626 | Smedley et al. | Jun 2006 | A1 |
20060129141 | Lin | Jun 2006 | A1 |
20060149194 | Conston et al. | Jul 2006 | A1 |
20060154981 | Klimko et al. | Jul 2006 | A1 |
20060155238 | Shields | Jul 2006 | A1 |
20060155265 | Juhasz et al. | Jul 2006 | A1 |
20060155300 | Stamper et al. | Jul 2006 | A1 |
20060167421 | Quinn | Jul 2006 | A1 |
20060167466 | Dusek | Jul 2006 | A1 |
20060173397 | Tu et al. | Aug 2006 | A1 |
20060173399 | Rodgers et al. | Aug 2006 | A1 |
20060178674 | McIntyre | Aug 2006 | A1 |
20060189915 | Camras et al. | Aug 2006 | A1 |
20060189916 | Bas et al. | Aug 2006 | A1 |
20060189917 | Mayr et al. | Aug 2006 | A1 |
20060195055 | Bergheim et al. | Aug 2006 | A1 |
20060195056 | Bergheim et al. | Aug 2006 | A1 |
20060195187 | Stegmann et al. | Aug 2006 | A1 |
20060200113 | Haffner et al. | Sep 2006 | A1 |
20060224146 | Lin | Oct 2006 | A1 |
20060241749 | Tu et al. | Oct 2006 | A1 |
20060259021 | Lin | Nov 2006 | A1 |
20060264971 | Akahoshi | Nov 2006 | A1 |
20060276759 | Kinast et al. | Dec 2006 | A1 |
20070010827 | Tu et al. | Jan 2007 | A1 |
20070021725 | Villette | Jan 2007 | A1 |
20070027452 | Varner et al. | Feb 2007 | A1 |
20070073275 | Conston et al. | Mar 2007 | A1 |
20070088432 | Solovay et al. | Apr 2007 | A1 |
20070093794 | Wang et al. | Apr 2007 | A1 |
20070093796 | Raksi et al. | Apr 2007 | A1 |
20070106200 | Levy | May 2007 | A1 |
20070106236 | Coroneo | May 2007 | A1 |
20070112292 | Tu et al. | May 2007 | A1 |
20070118147 | Smedley et al. | May 2007 | A1 |
20070121120 | Schachar | May 2007 | A1 |
20070135681 | Chin et al. | Jun 2007 | A1 |
20070173791 | Raksi | Jul 2007 | A1 |
20070179520 | West | Aug 2007 | A1 |
20070191863 | De Juan, Jr. et al. | Aug 2007 | A1 |
20070202186 | Yamamoto et al. | Aug 2007 | A1 |
20070208325 | Kurtz | Sep 2007 | A1 |
20070219509 | Tashiro et al. | Sep 2007 | A1 |
20070219541 | Kurtz | Sep 2007 | A1 |
20070235543 | Zadoyan et al. | Oct 2007 | A1 |
20070236771 | Zadoyan et al. | Oct 2007 | A1 |
20070265582 | Kaplan et al. | Nov 2007 | A1 |
20070270945 | Kobayashi et al. | Nov 2007 | A1 |
20070276315 | Haffner et al. | Nov 2007 | A1 |
20070276316 | Haffner et al. | Nov 2007 | A1 |
20070282244 | Tu et al. | Dec 2007 | A1 |
20070282245 | Tu et al. | Dec 2007 | A1 |
20070293807 | Lynch | Dec 2007 | A1 |
20070293872 | Peyman | Dec 2007 | A1 |
20070298068 | Badawi et al. | Dec 2007 | A1 |
20080015488 | Tu et al. | Jan 2008 | A1 |
20080027519 | Guerrero | Jan 2008 | A1 |
20080045878 | Bergheim et al. | Feb 2008 | A1 |
20080058704 | Hee et al. | Mar 2008 | A1 |
20080058777 | Kurtz et al. | Mar 2008 | A1 |
20080082088 | Kurtz et al. | Apr 2008 | A1 |
20080091224 | Griffis et al. | Apr 2008 | A1 |
20080119827 | Kurtz et al. | May 2008 | A1 |
20080228127 | Burns et al. | Sep 2008 | A1 |
20080278687 | Somani | Nov 2008 | A1 |
20080288082 | Deal | Nov 2008 | A1 |
20080312661 | Downer et al. | Dec 2008 | A1 |
20090005852 | Gittings et al. | Jan 2009 | A1 |
20090028953 | Yamamoto et al. | Jan 2009 | A1 |
20090030363 | Gellman | Jan 2009 | A1 |
20090030381 | Lind et al. | Jan 2009 | A1 |
20090036843 | Erskine | Feb 2009 | A1 |
20090043321 | Conston et al. | Feb 2009 | A1 |
20090054723 | Khairkhahan et al. | Feb 2009 | A1 |
20090069786 | Vesely et al. | Mar 2009 | A1 |
20090082860 | Schieber | Mar 2009 | A1 |
20090082862 | Schieber et al. | Mar 2009 | A1 |
20090104248 | Rapacki et al. | Apr 2009 | A1 |
20090118716 | Brownell | May 2009 | A1 |
20090118717 | Brownell et al. | May 2009 | A1 |
20090118718 | Raksi et al. | May 2009 | A1 |
20090131921 | Kurtz et al. | May 2009 | A1 |
20090132040 | Frion | May 2009 | A1 |
20090137988 | Kurtz | May 2009 | A1 |
20090138081 | Bergheim et al. | May 2009 | A1 |
20090157062 | Hauger et al. | Jun 2009 | A1 |
20090171327 | Kurtz et al. | Jul 2009 | A1 |
20090182421 | Silvestrini et al. | Jul 2009 | A1 |
20090198248 | Yeung et al. | Aug 2009 | A1 |
20090204053 | Nissan et al. | Aug 2009 | A1 |
20090247955 | Yamamoto et al. | Oct 2009 | A1 |
20090259126 | Saal et al. | Oct 2009 | A1 |
20090281520 | Highley et al. | Nov 2009 | A1 |
20090281530 | Korn | Nov 2009 | A1 |
20090291423 | Hara | Nov 2009 | A1 |
20100004580 | Lynch et al. | Jan 2010 | A1 |
20100036488 | de Juan et al. | Feb 2010 | A1 |
20100057072 | Roman et al. | Mar 2010 | A1 |
20100114309 | de Juan et al. | May 2010 | A1 |
20100137981 | Silvestrini et al. | Jun 2010 | A1 |
20100173866 | Hee et al. | Jul 2010 | A1 |
20100191176 | Ho et al. | Jul 2010 | A1 |
20100191177 | Chang et al. | Jul 2010 | A1 |
20100234726 | Sirimanne et al. | Sep 2010 | A1 |
20100234790 | Tu et al. | Sep 2010 | A1 |
20100262174 | Sretavan et al. | Oct 2010 | A1 |
20100324543 | Kurtz et al. | Dec 2010 | A1 |
20100331858 | Simaan | Dec 2010 | A1 |
20110009874 | Wardle et al. | Jan 2011 | A1 |
20110009958 | Wardle | Jan 2011 | A1 |
20110028948 | Raksi et al. | Feb 2011 | A1 |
20110028949 | Raksi et al. | Feb 2011 | A1 |
20110028950 | Raksi et al. | Feb 2011 | A1 |
20110028951 | Raksi et al. | Feb 2011 | A1 |
20110028952 | Raksi et al. | Feb 2011 | A1 |
20110028953 | Raksi et al. | Feb 2011 | A1 |
20110028954 | Raksi et al. | Feb 2011 | A1 |
20110028955 | Raksi | Feb 2011 | A1 |
20110028957 | Raksi et al. | Feb 2011 | A1 |
20110028958 | Raksi et al. | Feb 2011 | A1 |
20110098809 | Wardle et al. | Apr 2011 | A1 |
20110196487 | Badawi et al. | Aug 2011 | A1 |
20110218523 | Robl | Sep 2011 | A1 |
20110224597 | Stegmann et al. | Sep 2011 | A1 |
20110319806 | Wardle | Dec 2011 | A1 |
20120010702 | Stegmann et al. | Jan 2012 | A1 |
20120021397 | Van Dalen et al. | Jan 2012 | A1 |
20120022424 | Yamamoto et al. | Jan 2012 | A1 |
20120035524 | Silvestrini | Feb 2012 | A1 |
20120191064 | Conston et al. | Jul 2012 | A1 |
20120271272 | Hammack et al. | Oct 2012 | A1 |
20120283557 | Berlin | Nov 2012 | A1 |
20120302861 | Marshall et al. | Nov 2012 | A1 |
20130023837 | Becker | Jan 2013 | A1 |
20130150959 | Schieber et al. | Jun 2013 | A1 |
20130182223 | Wardle et al. | Jul 2013 | A1 |
20130184631 | Pinchuk | Jul 2013 | A1 |
20130253402 | Badawi et al. | Sep 2013 | A1 |
20130253403 | Badawi et al. | Sep 2013 | A1 |
20130253437 | Badawi et al. | Sep 2013 | A1 |
20130253438 | Badawi et al. | Sep 2013 | A1 |
20130253528 | Haffner et al. | Sep 2013 | A1 |
20130267887 | Kahook et al. | Oct 2013 | A1 |
20130281908 | Schaller et al. | Oct 2013 | A1 |
20140018720 | Horvath et al. | Jan 2014 | A1 |
20140066821 | Freidland et al. | Mar 2014 | A1 |
20140066831 | Silvestrini et al. | Mar 2014 | A1 |
20140081195 | Clauson et al. | Mar 2014 | A1 |
20140249463 | Wardle et al. | Sep 2014 | A1 |
20150018746 | Hattenbach | Jan 2015 | A1 |
20150022780 | John et al. | Jan 2015 | A1 |
20150038893 | Haffner et al. | Feb 2015 | A1 |
20150045714 | Horvath et al. | Feb 2015 | A1 |
20150057591 | Horvath et al. | Feb 2015 | A1 |
20150119787 | Wardle et al. | Apr 2015 | A1 |
20150223983 | Schieber et al. | Aug 2015 | A1 |
20150250649 | Euteneuer et al. | Sep 2015 | A1 |
20150282982 | Schieber et al. | Oct 2015 | A1 |
20150290033 | Wardle et al. | Oct 2015 | A1 |
20150305939 | Vera et al. | Oct 2015 | A1 |
20150305940 | Vera et al. | Oct 2015 | A1 |
20150313759 | Vera et al. | Nov 2015 | A1 |
20150366710 | Schieber et al. | Dec 2015 | A1 |
20160051406 | Wardle et al. | Feb 2016 | A1 |
20170143541 | Badawi et al. | May 2017 | A1 |
20170172794 | Varner et al. | Jun 2017 | A1 |
20170172795 | Lerner | Jun 2017 | A1 |
20170172799 | Horvath | Jun 2017 | A1 |
20170172800 | Romoda et al. | Jun 2017 | A1 |
20170202708 | Berlin | Jul 2017 | A1 |
20170239272 | Ambati et al. | Aug 2017 | A1 |
20170281409 | Haffner et al. | Oct 2017 | A1 |
20170290705 | Wardle et al. | Oct 2017 | A1 |
20180360655 | Berlin | Dec 2018 | A1 |
20180369017 | Schieber et al. | Dec 2018 | A1 |
20190343679 | Wardle et al. | Nov 2019 | A1 |
20190380873 | Berlin | Dec 2019 | A1 |
20190380874 | Schieber et al. | Dec 2019 | A1 |
20200060876 | Wardle et al. | Feb 2020 | A1 |
20200085620 | Euteneuer et al. | Mar 2020 | A1 |
20200197221 | Schieber et al. | Jun 2020 | A1 |
20200222238 | Schieber et al. | Jul 2020 | A1 |
20200261270 | Berlin | Aug 2020 | A1 |
20210030590 | Blanda et al. | Feb 2021 | A1 |
Number | Date | Country |
---|---|---|
199876197 | Feb 1999 | AU |
1950091 | Apr 2007 | CN |
4226476 | Aug 1993 | DE |
102012221350 | May 2014 | DE |
0168201 | Jun 1988 | EP |
0957949 | Nov 1996 | EP |
0766544 | May 1998 | EP |
1615604 | Aug 2009 | EP |
2193821 | Jun 2010 | EP |
1715827 | Dec 2010 | EP |
2380622 | Oct 2011 | EP |
2468327 | Jun 2012 | EP |
2471563 | Jul 2012 | EP |
1833440 | Aug 2012 | EP |
1732484 | Aug 2017 | EP |
1740153 | Aug 2017 | EP |
3205333 | Aug 2017 | EP |
H10-504978 | May 1998 | JP |
11123205 | May 1999 | JP |
2002542872 | Dec 2002 | JP |
2006517848 | Aug 2006 | JP |
2006289075 | Oct 2006 | JP |
2010509003 | Mar 2010 | JP |
2011502649 | Jan 2011 | JP |
WO9620742 | Jul 1996 | WO |
WO9901063 | Jan 1999 | WO |
WO9945868 | Sep 1999 | WO |
WO 0007525 | Feb 2000 | WO |
WO0013627 | Mar 2000 | WO |
WO 0064389 | Nov 2000 | WO |
WO 0064393 | Nov 2000 | WO |
WO0067687 | Nov 2000 | WO |
WO0189437 | Nov 2001 | WO |
WO 0197727 | Dec 2001 | WO |
WO 0236052 | May 2002 | WO |
WO 02074052 | Sep 2002 | WO |
WO 02080811 | Oct 2002 | WO |
WO 03015659 | Feb 2003 | WO |
WO 03045290 | Jun 2003 | WO |
WO 2004054643 | Jul 2004 | WO |
WO 2004093761 | Nov 2004 | WO |
WO 2005105197 | Nov 2005 | WO |
WO 2006066103 | Jun 2006 | WO |
WO 2007035356 | Mar 2007 | WO |
WO 2007047744 | Apr 2007 | WO |
WO 2007087061 | Aug 2007 | WO |
WO 2008002377 | Jan 2008 | WO |
WO 2008005873 | Jan 2008 | WO |
WO 2009120960 | Oct 2009 | WO |
WO 2011053512 | May 2011 | WO |
WO 2011057283 | May 2011 | WO |
WO 2011106781 | Sep 2011 | WO |
WO 2011150045 | Dec 2011 | WO |
WO 2012051575 | Apr 2012 | WO |
WO2012083143 | Jun 2012 | WO |
WO 2013147978 | Oct 2013 | WO |
Entry |
---|
Euteneuer et al.; U.S. Appl. No. 15/601,756 entitled “Methods and apparatus for treating glaucoma,” filed May 22, 2017. |
Kirkness et al.; The Use of Silicone Drainage Tubing to Control Post-Keratoplasty Glaucoma; Eye; 2 (pt 5); pp. 583-590; Apr. 1988. |
Molteno et al.; Long Tube Implants in the Management of Glaucoma; SA Medical Journal; 26; pp. 1062-1066; Jun. 1976. |
Molteno; New implant for drainage in glaucoma; Brit. J. Ophthal; 53; pp. 606-615; Sep. 1969. |
Schocket et al.; Anterior Chamber Tube Shunt to an Encircling Band in the Treatment of Neovascular Glaucoma and other Refractory Glaucomas; Ophthalmology; 92; pp. 553-562; Apr. 1985. |
Wilcox et al.; Hypothesis for Improving Accessory Filtration by Using Geometry; Journal of Glaucoma; 3; pp. 244-247; Fall 1994. |
Schieber; U.S. Appl. No. 15/325,628 entitled “Ocular implant delivery system and method,” filed Jan. 11, 2017. |
Bahler, et al.; Trabecular bypass stents decrease intraocular pressure in cultured human anterior segments; Amer. Journal of Ophthalmology; vol. 138, No. 6; pp. 988-994.e2; Dec. 2004. |
Camras et al.; A novel schlemm's canal scaffold increases outflow facility in a human anterior segment perfusion model; Invest. Opthalmol. Vis. Sci. ; 53(10); pp. 6115-6121; Sep. 1, 2012. |
D'Ermo, et al.; Our results with the operation of ab externo trabeculotomy; Ophthalmologica; vol. 163; pp. 347-355; Feb. 1971. |
Ellingsen et al.; Trabeculotomy and sinusotomy in enucleated human eyes; Investigative Ophthalmology; vol. 11; pp. 21-28; Jan. 1972. |
Grant; Experimental aqueous perfusion in enucleated human eyes; Archives of Ophthalmology; vol. 69; pp. 783-801; Jun. 1963. |
Gulati et al; A novel 8-mm schlemm's canal scaffold reduces outflow resistance in a human anterior segment perfusion model; Invest. Ophthalmol. Vis. Sci.; 54(3); pp. 1698-1704; Mar. 5, 2013. |
Johnstone et al.; “Microsurgery of Schlemm's Canal and the Human Aqueous Outflow System;” American Journal of Ophthalmology, vol. 76 (6): 906-917; Dec. 1973. |
Lee et al.; Aqueous-venous shunt and intraocular pressure. Preliminary report of animal studies; Investigative Ophthalmology; vol. 5; No. 1; pp. 59-64; Feb. 1966. |
Lynch, Mary G.; U.S. Appl. No. 60/131,030 entitled “Devices and methods for treating glaucoma by enhancing aqueous outflow through schlemm's canal and anterior chamber angle,” filed Apr. 26, 1999. |
Moses, Robert; The effect of intraocular pressure on resistance to outflow; Survey of Ophthalmology; vol. 22; No. 2; pp. 88-100; Sep.-Oct. 1977. |
Mäepea et al.; The pressures in the episcleral veins, schlemm's canal and the trabecular meshwork in monkeys: effects of changes in intraocular pressure; Exp. Eye Res.; vol. 49; pp. 645-663; Oct. 1989. |
Rosenquist et al.; Outflow resistance of enucleated human eyes at two different perfusion pressures and different extents of trabeculotomy; Current Eye Res.; vol. 8; No. 12; pp. 1233-1240; Dec. 1989. |
Savage, James; Gonioscopy in the management of glaucoma; Am. Academy of Ophthalmology; Focal Points; vol. XXIV; No. 3; pp. 1-14; Mar. 2006. |
Schultz, Jared; Canaloplasty procedure shows promise for open-angle glaucoma in European study; Ocular Surgery News; vol. 34; Mar. 1, 2007. |
Smit et al.; Effects of viscoelastic injection into schlemm's canal in primate and human eyes; J. Am. Academy of Ophthalmology; vol. 109; No. 4; pp. 786-792; Apr. 2002. |
Spiegel et al.; Schlemm's canal implant: a new method to lower intraocular pressure in patients with POAG?; Ophthalmic Surgery and Lasers; vol. 30; No. 6; pp. 492-494; Jun. 1999. |
Schieber et al.; U.S. Appl. No. 15/012,544 entitled “Methods and devices for increasing aqueous humor outflow,” filed Feb. 1, 2016. |
Cambridge Dictionary; Sensor (definition); 2 pages; retrived from the internet (http://dictionary.cambridge.org/define.asp?dict=CALD&key=71811 >) on Aug. 14, 2018. |
Dietlein et al.; Morphological variability of the trabecular meshwork in glaucoma patients: implications for non-perforating glaucoma surgery; British Journal of Ophthalmology; 84(12); pp. 1354-1359; Dec. 2000. |
Huang et al.; Optical coherence tomography; Science; 254(5035); pp. 1178-1181; 12 pages (Author Manuscript); Nov. 1991. |
Johnstone; Aqueous humor outflow system overview; Becker-Shaffer's Diagnosis and Therapy of the Glaucomas; Part 2 Aqueous Humor Dynamics; Chapter 3; pp. 25-46; Mosby Elseveir; (year of pub. sufficiently earlier than effective US filed and any foreign priority date) 2009. |
Lee et al.; Short-pulsed neodymium-YAG laser trabeculotomy. An in vivo morphological study in the human eye; Investigative Ophthalmology and Visual Science; 29(11); pp. 1698-1707; Nov. 1988. |
Macmilla Online Dictionary; Detector (definition); Macmilla on Line Dictionary; 2 pages; retrived from the internet (https://www.macmillandictionary.com/dictionary/british/detector) on Aug. 14, 2018. |
Nakamura et al.; Femtosecond laser photodisruption of primate trabecular meshwork: an ex vivo study; Investigative Ophthalmology and Visual Science; 50(3); pp. 1198-1204; Mar. 2009. |
Owen; A moving-mirror gonioscope for retinal surgery; British Journal of Ophthalmology; 61(3); pp. 246-247; Mar. 1977. |
Oxford Dictionaries; Detector (definition); 1 page; retrieved from the internet (https://en.oxforddictionaries.com/definition/detector) on Aug. 14, 2018. |
Oxford Dictionaries; Sensor (definition); 1 page; retrieved from te internet (http://www.askoxford.com/concise_oed/sensor?view=uk>) on Aug. 14, 2018. |
Radhakrishnan et al.; Real-time optical coherence tomography of the anterior segment at 1310 nm; Archives of Opthhalmology; 119(8); pp. 1179-1185; Aug. 2001. |
Toyran et al.; Femtosecond laser photodisruption of human trabecular meshwork: an in vitro study; Experimental Eye Research; 81(3); pp. 298-305; Sep. 2005. |
Van Meter et al.; U.S. Appl. No. 15/751,886 entitled “Ocular implant with pressure sensor and delivery system,” filed Feb. 12, 2018. |
Berlin; U.S. Appl. No. 16/196,260 entitled “Delivery system and method of use for the eye,” filed Nov. 20, 2018. |
Sugyama et al.; Micro-Diaphragm Pressure Sensor; 1986 International Electron Devices Meeting; pp. 184-187; Dec. 7, 1986. |
Number | Date | Country | |
---|---|---|---|
20160250072 A1 | Sep 2016 | US |
Number | Date | Country | |
---|---|---|---|
61635104 | Apr 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13793638 | Mar 2013 | US |
Child | 15150175 | US |